Canadian application, no grantCanada
Pharmacological agents
CA 2285192 A1 · Owner: Iyengar, Smriti · Inventors: Iyengar, Smriti; Lodge, David; Bleakman, David
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Antagonists selective for the GluR5 receptor are useful for the treatment of pain. Also disclosed are novel decahydroisoquinoline derivatives which are selective GluR5 receptor antagonists.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 6, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 6, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 6, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledApril 6, 1998
GrantedNo grant recorded
Term endedApril 6, 2018
Patent numberCA 2285192 A1
Classification (IPC)C07D217/06 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.